“FMS highest international salary at Rs 26 lakh (Business Standard India)” plus 3 more |
- FMS highest international salary at Rs 26 lakh (Business Standard India)
- International clinical program for Medtronic's CoreValve transcatheter aortic valve system commenced (News-Medical-Net)
- Institute for Worship Studies Earns Accredited Status (Christian News Wire)
- Medtronic Starts International Study Of CoreValve(R) Transcatheter Aortic Valve System (Medical News Today)
| FMS highest international salary at Rs 26 lakh (Business Standard India) Posted: 14 Mar 2010 11:45 AM PDT
| The Delhi-based Faculty of Management Studies (FMS) has recorded a highest international salary of Rs 26 lakh compared with Rs 20 lakh domestically that was offered by a supply chain consulting firm. Last year, the highest domestic salary was Rs 19 lakh from Microsoft. After a relative lull last year, consulting firms, with one of the most coveted job profiles, were back in a major way with 18 per cent of the batch opting for jobs in this domain. Also, 4 new investment banks visited the campus besides some domestic banks. "This year saw a shift in the general pecking order with students giving more importance to the job content and profile offered as opposed to the customary factors of compensation and brand name," said a statement from the institute. FMS operates from two campuses and offers both full time and part time MBA programmes. It offers the flagship two year MBA programme from north campus and the full time MBA- Management of Services programme from south campus. The average domestic salary for the MBA batch of 2010 touched Rs 13.1 lakh per annum, an increase of 12.5 per cent over last year and nearly 36 per cent of the batch opted for a career in finance, closely followed by marketing with 29 per cent. Consulting drew in 18 per cent of the batch with IT and operations also hitting the double digit mark at 10 per cent. "With the economy on an upswing, placements for the class of 2010 afforded students the opportunity to apply to a gamut of companies — consultancies, I-banks, FMCGs, IT and operations — amongst others. We are pleased to see the increase in maturity amongst students in shaping their future careers. There has been a greater focus on practical aspects of a job including profile, function, career track, growth prospects and culture fit with an organisation over compensation and brand name. Over the next few years, we hope to strengthen this trend in FMS Delhi," said Prof (Dr) Madhu Vij, Placement Convenor at FMS. Commercial Banks like Standard Chartered, CitiBank, HSBC, Axis Bank, Yes Bank, ICICI Bank were the single biggest recruiters with more than 20 offers. Marketing profiles were offered by HUL, P&G, ITC, Cadbury, Britannia, Dabur, Godrej, Reckitt Benckiser, Pepsico. Consulting firms like Accenture Business Consulting, CEB, Deloitte, HCL Infosystems, Hewitt Associates, KPMG, Technopak made recruitment besides general management roles that were offered by TAS, Mahindra and Mahindra and Essar Group. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Posted: 14 Mar 2010 10:45 PM PDT Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc. (NYSE: MDT), today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement.
The CoreValve Advance clinical study began enrolling patients last week, with the first two implants occurring in Germany. CoreValve Advance is a prospective, observational international post-market study to evaluate clinical outcomes of patients with severe aortic stenosis who are treated with the CoreValve system in standard clinical practice. The CoreValve system received CE (Conformité Européenne) Mark in March 2007. It is not yet available in the United States for commercial sale or clinical use. "The CoreValve Advance study is Medtronic's first major clinical evaluation of the CoreValve system since we acquired it in April 2009," said cardiac surgeon Dr. John Liddicoat, vice president and general manager of the Structural Heart division, part of the CardioVascular business, at Medtronic. "The study demonstrates our commitment to leverage Medtronic's global clinical research expertise to strengthen the body of evidence for this breakthrough medical device. "It is one of several CoreValve studies planned to begin this year worldwide as part of a rigorous, long-term clinical program to be further enhanced by innovative system advancements." Approximately 1,000 patients with severe aortic stenosis will be enrolled in CoreValve Advance at up to 90 clinical trial sites in countries where the CoreValve system is commercially available. Most of the trial sites will be in Europe, where the CoreValve system is used in approximately 75 percent of transcatheter aortic valve replacements involving percutaneous femoral access. The principal and co-principal investigators of CoreValve Advance are Prof. Axel Linke, Universität Leipzig Herzzentrum, and Prof. Robert Bauernschmitt, Deutches Herzzentrum München, both in Germany. The first study procedures were performed by Prof. Horst Sievert, CardioVascular Center Frankfurt, also in Germany. "We have been very pleased with past clinical results using the CoreValve system, and we anticipate great scientific value for future patients by participating in the CoreValve Advance study," said Prof. Sievert. "The resulting data will provide important information to physicians and regulatory officials worldwide related to broad-scale safety and device performance for patients with severe aortic stenosis who often are at high risk for open-heart surgery." Study patients will be followed for at least five years following implantation of CoreValve. The primary endpoint is Major Adverse Cardiac & Cerebrovascular Events (MACCE) at 30 days following the procedure, with MACCE defined as a composite of: all-cause mortality; myocardial infarction; emergent cardiac surgery or percutaneous re-intervention; and stroke. The study also includes 19 secondary endpoints and data collection related to the health economic impact of CoreValve on patient quality of life and therapy cost-effectiveness. The CoreValve system is designed to enable replacement of a diseased aortic valve without open-heart surgery or surgical removal of the native valve. Typically delivered through the femoral artery, it has been implanted in more than 7,500 patients worldwide and is now available in 29 countries outside the United States. Medtronic CardioVascular is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through innovation and collaboration with leading clinicians, researchers and scientists worldwide. SOURCE Medtronic, Inc. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
| Institute for Worship Studies Earns Accredited Status (Christian News Wire) Posted: 14 Mar 2010 01:56 PM PDT
|
2020 Pennsylvania Ave., NW
202-546-0054
One Penn Plaza, Suite 6202
212-290-1585
One Penn Plaza, Suite 6202
212-290-1585
Religion Newswire 202-546-0054
2020 Pennsylvania Ave., NW Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Posted: 14 Mar 2010 05:17 AM PDT  Main Category: Cardiovascular / Cardiology Also Included In: Heart Disease; Medical Devices / Diagnostics Article Date: 14 Mar 2010 - 1:00 PST Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic, Inc. (NYSE: MDT), announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic valve replacement. The CoreValve Advance clinical study began enrolling patients last week, with the first two implants occurring in Germany. CoreValve Advance is a prospective, observational international post-market study to evaluate clinical outcomes of patients with severe aortic stenosis who are treated with the CoreValve system in standard clinical practice. The CoreValve system received CE (Conformité Européenne) Mark in March 2007. It is not yet available in the United States for commercial sale or clinical use. "The CoreValve Advance study is Medtronic's first major clinical evaluation of the CoreValve system since we acquired it in April 2009," said cardiac surgeon Dr. John Liddicoat, vice president and general manager of the Structural Heart division, part of the CardioVascular business, at Medtronic. "The study demonstrates our commitment to leverage Medtronic's global clinical research expertise to strengthen the body of evidence for this breakthrough medical device. "It is one of several CoreValve studies planned to begin this year worldwide as part of a rigorous, long-term clinical program to be further enhanced by innovative system advancements." Approximately 1,000 patients with severe aortic stenosis will be enrolled in CoreValve Advance at up to 90 clinical trial sites in countries where the CoreValve system is commercially available. Most of the trial sites will be in Europe, where the CoreValve system is used in approximately 75 percent of transcatheter aortic valve replacements involving percutaneous femoral access. The principal and co-principal investigators of CoreValve Advance are Prof. Axel Linke, Universität Leipzig Herzzentrum, and Prof. Robert Bauernschmitt, Deutches Herzzentrum München, both in Germany. The first study procedures were performed by Prof. Horst Sievert, CardioVascular Center Frankfurt, also in Germany. "We have been very pleased with past clinical results using the CoreValve system, and we anticipate great scientific value for future patients by participating in the CoreValve Advance study," said Prof. Sievert. "The resulting data will provide important information to physicians and regulatory officials worldwide related to broad-scale safety and device performance for patients with severe aortic stenosis who often are at high risk for open-heart surgery." Study patients will be followed for at least five years following implantation of CoreValve. The primary endpoint is Major Adverse Cardiac & Cerebrovascular Events (MACCE) at 30 days following the procedure, with MACCE defined as a composite of: all-cause mortality; myocardial infarction; emergent cardiac surgery or percutaneous re-intervention; and stroke. The study also includes 19 secondary endpoints and data collection related to the health economic impact of CoreValve on patient quality of life and therapy cost-effectiveness. The CoreValve system is designed to enable replacement of a diseased aortic valve without open-heart surgery or surgical removal of the native valve. Typically delivered through the femoral artery, it has been implanted in more than 7,500 patients worldwide and is now available in 29 countries outside the United States. Medtronic CardioVascular is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through innovation and collaboration with leading clinicians, researchers and scientists worldwide.
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions. Contact Our News Editors For any corrections of factual information, or to contact the editors please use our feedback form. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
email to a friend
printer friendly
view / write opinions| You are subscribed to email updates from Yahoo! News Search Results for International Studies To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment